DPP Inhibitors

Dipeptidyl peptidase-4 (DPP-4), also known as CD26, is a ubiquitous serine protease that exists both as a membrane-bound protein and in a soluble form in the plasma. Its primary metabolic function is the rapid degradation of incretin hormones, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These incretins are secreted by the gut in response to food intake and play a vital role in glucose homeostasis by stimulating insulin secretion from pancreatic beta cells and suppressing glucagon release from alpha cells in a glucose-dependent manner. Because GLP-1 and GIP are inactivated by DPP-4 within minutes, inhibiting this enzyme extends the half-life of endogenous incretins, thereby enhancing the body's natural insulin response to meals. DPP-4 inhibitors, commonly known as "gliptins," are a well-established class of oral glucose-lowering agents used in the management of Type 2 Diabetes Mellitus (T2DM). They are favored for their low risk of hypoglycemia (since their action is glucose-dependent) and their weight-neutral profile, making them an attractive option for patients who cannot tolerate other medications or as add-on therapy to metformin.

Approved agents in this class include sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin. The classification of DPP-4 inhibitors is based on their chemical structure and binding kinetics. They are generally divided into peptidomimetics (e.g., vildagliptin and saxagliptin), which often form a covalent bond with the active site serine of the enzyme, and non-peptidomimetics (e.g., sitagliptin and alogliptin), which bind through non-covalent interactions. Linagliptin is unique for its primarily non-renal excretion, making it the preferred choice for patients with significant renal impairment. Current research is investigating the pleiotropic effects of DPP-4 inhibition beyond glycemic control. Since DPP-4 has many other substrates, including chemokines and neuropeptides, its inhibition may influence inflammation, cardiovascular health, and wound healing.

Some studies suggest potential cardioprotective and anti-inflammatory benefits, although large-scale cardiovascular outcome trials (CVOTs) like SAVOR-TIMI 53 and TECOS have primarily demonstrated cardiovascular safety rather than a significant reduction in major adverse cardiovascular events. A notable challenge in the class has been the concern over a potential increased risk of heart failure hospitalization (specifically noted with saxagliptin) and rare reports of acute pancreatitis, though subsequent meta-analyses have provided some reassurance. In the current therapeutic landscape, DPP-4 inhibitors face stiff competition from GLP-1 receptor agonists and SGLT2 inhibitors, which have shown superior benefits in weight loss and cardiorenal protection. However, the oral bioavailability, excellent tolerability, and simplicity of the gliptin regimen ensure their continued relevance. Future directions include the exploration of DPP-4 inhibitors in combination with other novel metabolic agents and their potential role in treating non-alcoholic steatohepatitis (NASH) or other inflammatory conditions where CD26 signaling is implicated. The dual role of CD26 as an enzyme and a costimulatory molecule in T-cell activation also suggests potential applications in immunology.

Talabostat (Val-boroPro, PT-100) Mesylate from Selleck Targets FAP to Elevate Active FGF21
Talabostat (Val-boroPro, PT-100) Mesylate from Selleck Targets FAP to Elevate Active FGF21